Hiroshi Kodama1, Laurien G Vroomen1, Eisuke Ueshima1, Jennifer Reilly1, Whitney Brandt2, Lee-Ronn Paluch3, Sebastien Monette4, David Jones2, Stephen B Solomon5, Govindarajan Srimathveeravalli6. 1. Interventional Radiology Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY. 2. Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. 3. Center of Comparative Medicine and Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Hospital for Special Surgery, New York, NY. 4. Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY. 5. Interventional Radiology Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Radiology, Weill Cornell Medical College, New York, NY. 6. Interventional Radiology Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Radiology, Weill Cornell Medical College, New York, NY. Electronic address: srimaths@mskcc.org.
Abstract
OBJECTIVE: To evaluate the feasibility of catheter-based endobronchial electroporation for the treatment of peribronchial tumors and assess the incidence of treatment-related adverse events. METHODS: Cytotoxicity of electroporation with or without cisplatin or gefitinib was assessed in vitro with lung cancer and normal cell lines. A novel catheter was designed for endobronchial electroporation, and computer simulations were used to predict in vivo treatment effects. Electroporation with the test catheter was performed (2000 V, 70 pulses) in the main bronchus of 8 pigs at 11 locations. Computed tomography imaging was performed before they were killed at 4 hours (6 animals) or 4 weeks (2 animals) posttreatment. Treated airway and surrounding parenchyma were compared with sham treatment via gross and histopathology. RESULTS: Significant cell death due to electroporation and increased cytotoxicity in combination with cisplatin or gefitinib were observed in cancer cells only (P < .05). Simulations predicted penetrative electroporation of peribronchial parenchyma without tissue heating. Electric pulse delivery in vivo induced transient venous and bronchial spasms that resolved without intervention. Cross-sectional measurement of electroporation effects on computed tomography (14.4 ± 1.4 by 10.5 ± 1.3 mm) and gross pathology (17.2 ± 3.0 by 8.8 ± 0.6 mm) were representative of values predicted by simulation (P < .001). Cell death due to irreversible electroporation was observed in bronchial and parenchymal tissue in acute tissue samples. Treated lung rapidly recovered from the effects of electroporation without change in bronchial patency at 4 weeks posttreatment. CONCLUSIONS: Catheter-based endobronchial electroporation is a reproducible technique that can be used to treat peribronchial tumors in combination with cisplatin, without affecting patency of the treated bronchus.
OBJECTIVE: To evaluate the feasibility of catheter-based endobronchial electroporation for the treatment of peribronchial tumors and assess the incidence of treatment-related adverse events. METHODS:Cytotoxicity of electroporation with or without cisplatin or gefitinib was assessed in vitro with lung cancer and normal cell lines. A novel catheter was designed for endobronchial electroporation, and computer simulations were used to predict in vivo treatment effects. Electroporation with the test catheter was performed (2000 V, 70 pulses) in the main bronchus of 8 pigs at 11 locations. Computed tomography imaging was performed before they were killed at 4 hours (6 animals) or 4 weeks (2 animals) posttreatment. Treated airway and surrounding parenchyma were compared with sham treatment via gross and histopathology. RESULTS: Significant cell death due to electroporation and increased cytotoxicity in combination with cisplatin or gefitinib were observed in cancer cells only (P < .05). Simulations predicted penetrative electroporation of peribronchial parenchyma without tissue heating. Electric pulse delivery in vivo induced transient venous and bronchial spasms that resolved without intervention. Cross-sectional measurement of electroporation effects on computed tomography (14.4 ± 1.4 by 10.5 ± 1.3 mm) and gross pathology (17.2 ± 3.0 by 8.8 ± 0.6 mm) were representative of values predicted by simulation (P < .001). Cell death due to irreversible electroporation was observed in bronchial and parenchymal tissue in acute tissue samples. Treated lung rapidly recovered from the effects of electroporation without change in bronchial patency at 4 weeks posttreatment. CONCLUSIONS: Catheter-based endobronchial electroporation is a reproducible technique that can be used to treat peribronchial tumors in combination with cisplatin, without affecting patency of the treated bronchus.
Authors: Wolfgang Gesierich; Frank Reichenberger; Andreas Fertl; Karl Haeussinger; Ronald Sroka Journal: J Thorac Cardiovasc Surg Date: 2014-01-15 Impact factor: 5.209
Authors: Govindarajan Srimathveeravalli; Mikhail Silk; Thomas Wimmer; Sebastien Monette; Simon Kimm; Majid Maybody; Stephen B Solomon; Jonathan Coleman; Jeremy C Durack Journal: J Vasc Interv Radiol Date: 2015-03-11 Impact factor: 3.464
Authors: Mikhail Silk; David Tahour; Govindarajan Srimathveeravalli; Stephen B Solomon; Raymond H Thornton Journal: Semin Intervent Radiol Date: 2014-06 Impact factor: 1.513
Authors: Mikhail T Silk; Thomas Wimmer; Kyungmouk S Lee; Govindarajan Srimathveeravalli; Karren T Brown; Peter T Kingham; Yuman Fong; Jeremy C Durack; Constantinos T Sofocleous; Stephen B Solomon Journal: J Vasc Interv Radiol Date: 2013-11-18 Impact factor: 3.464
Authors: Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett Journal: Nucleic Acids Res Date: 2012-11-23 Impact factor: 16.971
Authors: Maria Walls; Gerard M Walls; Jacqueline A James; Kyle T Crawford; Hossam Abdulkhalek; Tom B Lynch; Aaron J Peace; Terry E McManus; O Rhun Evans Journal: BMC Pulm Med Date: 2020-08-06 Impact factor: 3.317